Background: International funding for global health research is not systematically documented. We have assessed the level of research funding awarded by UK funders of international research to low-and middleincome countries or research institutions in these countries.
Introduction
The burden of disease is a major barrier to development in lowand middle-income countries. 1 However, health research is disproportionately concentrated in high-income countries and devoted to illnesses that affect richer populations. In 1999, a seminal paper by the Global Forum for Health Research documented the 10/90 gap: 10% of health research resources are devoted to the poorest 90% of the world's population. 2 Although funding for global health has substantially increased since 2000, 3 there remains a mismatch between burden and research financing. 2 Analysis of the financing of health research is complex, as the agencies that invest in health research use numerous organisations, channels and methods to distribute resources. A recent study analysed the infectious disease research funding received by UK institutions and their global partners from public and philanthropic sources, and highlighted substantial disparities between disease burden and funding. 4 In this paper we explore the relationship between research funding provided by UK funding agencies and the colonial links of the recipient countries to the UK. Specifically we analyse funding for research in countries outside the UK where investments for infectious disease research were allocated to a global partner institution or where much of the actual research was performed. We believe that our study is the first to systematically analyse investment outside the UK in infectious disease research.
Methods
We systematically searched databases and websites for information on investments in infectious disease research for the period 
Results
In sum, £264.3 million was invested across 522 studies (see Supplementary Table 1 ). Research investments were allocated primarily to Uganda (£107.0 million; 40.5%), Zimbabwe (£76.1 million; 28.8%), South Africa (£60.0 million; 22.7%), Malawi (£26.9 million; 10.2%), and Tanzania (£16.2 million; 6.1%) (Figure 1 ). These and four other African countries accounted for nine of the top 10 countries by total investment in the study period. India, the only non-African country in the top 10, was at number nine, with £12.2 million (4.6%). Research investment in countries with no colonial links to the UK was £29.8 million (11.3%).
HIV was the infection attracting the greatest investment (£133.3 million; 50.4%), followed by malaria (£44.5 million; 16.8%), neglected tropical diseases (NTDs; £41.0 million; 15.5%), tuberculosis (£20.0 million; 7.6%) and gastrointestinal infections (£14.3 million; 5.4%).
Analysis of funding along the research and development (R&D) value chain showed that operational research (£109.1 million; 41.3%), including epidemiological studies, was the major focus of funding, followed by clinical trials (£74.8 million; 28.3%), preclinical research (£60.0 million; 22.7%) and product development (£20.6 million; 7.8%). In terms of tools to tackle the burden of infectious diseases in low-and middle-income countries, vaccine research received £12.4 million, diagnostics £2.9 million and therapeutics £87.2 million (primarily for testing HIV antiretroviral regimens).
Analysis by funding organisation showed that the Wellcome Trust was the largest funder by size of investment (£120.4 million; 45.6%), followed by the Department for International Development (£77.2 million; 29.2%) and the Medical Research Council (£54.1 million; 20.5%).
Discussion
The findings suggest that UK funding for infectious disease research mirrors colonial ties, with most of the funding awarded during the period from 1997-2010 going to countries with colonial ties to the UK. Earlier studies have demonstrated funding for diseases such as malaria following a similar pattern, with investment reflecting colonial ties rather than disease burden. 5 Although prior colonial links and current collaborations through institutions such as the Commonwealth are important in establishing and maintaining collaborative links, it may be counter-productive to be allocating research funding to the countries where these links exist. Instead, research funding should be targeted to address the disease burden and be awarded on the basis of scientific excellence and implementation capability. Further work is needed to assess the extent to which these links are maintained in an effort to make reparation for past social and economic policies, which may have contributed greatly to the current local burden of disease, and is beyond the scope of this paper.
Investment of research funding is vitally important in addressing the disease burden worldwide and in fostering a greater sense of global solidarity, partnership and innovation. Unbalanced investment that directs resources primarily to countries with colonial ties, and those where wide use of the English language makes for ease of working and facilitates the maintenance of existing links, will neglect populations in great need elsewhere, and must be questioned on ethical and moral grounds.
Funding organisations and countries investing in health research should review their funding policies and assist countries without colonial ties or where English is not the official language International Health
